citalopram has been researched along with Acute Post-Traumatic Stress Disorder in 42 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objectives were to characterize latent depression subtypes by symptoms, evaluate sex differences in and examine correlates of these subtypes, and examine the association between subtype and symptom remission after citalopram treatment." | 9.20 | The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. ( Lapane, KL; Rothschild, AJ; Ulbricht, CM, 2015) |
| "Posttraumatic stress disorder (PTSD) is a trauma-induced mental disorder characterised by fear extinction dysfunction in which fear circuit monoamines are possibly associated." | 5.43 | Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory. ( Lin, CC; Liu, YP; Tung, CS, 2016) |
| "Citalopram treatment resulted in significant deactivation (p = 0." | 5.32 | Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. ( Carey, PD; Harvey, BH; Niehaus, DJ; Seedat, S; Stein, DJ; van der Linden, G; van Heerden, BB; Warwick, J, 2004) |
| "The objectives were to characterize latent depression subtypes by symptoms, evaluate sex differences in and examine correlates of these subtypes, and examine the association between subtype and symptom remission after citalopram treatment." | 5.20 | The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. ( Lapane, KL; Rothschild, AJ; Ulbricht, CM, 2015) |
| "Sertraline might be effective, though not statistically significant, in treating patients with post-traumatic brain injury depression." | 4.95 | Antidepressants for Depression Associated with Traumatic Brain Injury: A Meta-analytical Study of Randomised Controlled Trials. ( Katsanos, AH; Paraschakis, A, 2017) |
| "Our patient presented to the emergency department with priapism, approximately 3 months after beginning a pharmacologic regimen of escitalopram, prazosin, trazodone, and methylphenidate for PTSD." | 3.85 | Recurrent Priapism in a Military Veteran Receiving Treatment for PTSD. ( George, AK; Mann, RA, 2017) |
| "Forty-eight male veterans with PTSD (mean age: 52." | 2.87 | Influence of adjuvant mindfulness-based cognitive therapy (MBCT) on symptoms of post-traumatic stress disorder (PTSD) in veterans - results from a randomized control study. ( Brand, S; Holsboer-Trachsler, E; Jasbi, M; Karami, G; Mirzaee, J; Omidbeygi, M; Panahi, A; Peyravi, M; Sadeghi Bahmani, D, 2018) |
| "Forty-five PTSD patients received 12 weeks of gradually increasing doses of escitalopram reaching 40 mg daily at 4 weeks." | 2.84 | Efficacy and Tolerability of High-Dose Escitalopram in Posttraumatic Stress Disorder. ( Gevonden, M; Qi, W; Shalev, A, 2017) |
| "The lingering prevalence of PTSD, despite efficient interventions, illustrates a nonremitting, treatment-refractory subset of survivors and outlines a major clinical and public health challenge." | 2.82 | Long-term outcome of early interventions to prevent posttraumatic stress disorder. ( Adessky, R; Ankri, Y; Freedman, S; Gilad, M; Israeli-Shalev, Y; Qian, M; Shalev, AY, 2016) |
| "Posttraumatic stress disorder (PTSD) is a chronic disabling illness, resulting from exposure to extreme traumatic event." | 2.79 | Baclofen add-on to citalopram in treatment of posttraumatic stress disorder. ( Haghighi, MB; Hebrani, P; Javanbakht, A; Manteghi, AA; Mortezania, M, 2014) |
| "Survivors who met PTSD symptom criteria during the clinical assessment were invited to receive treatment." | 2.77 | Prevention of posttraumatic stress disorder by early treatment: results from the Jerusalem Trauma Outreach And Prevention study. ( Adessky, R; Ankri, Y; Freedman, S; Israeli-Shalev, Y; Peleg, T; Shalev, AY, 2012) |
| "Despite a substantial improvement in PTSD symptoms, there was virtually no change in BDNF levels over time." | 2.75 | Serum brain-derived neurotrophic factor predicts responses to escitalopram in chronic posttraumatic stress disorder. ( Berger, W; Lenoci, M; Marmar, CR; Mehra, A; Mellon, SH; Metzler, TJ; Neylan, TC; Otte, C; Tarasovsky, G; Wolkowitz, OM, 2010) |
| "Escitalopram was well tolerated." | 2.74 | Escitalopram: an open-label study of bereavement-related depression and grief. ( Clayton, PJ; Hensley, PL; Slonimski, CK; Uhlenhuth, EH, 2009) |
| "Citalopram was delivered using measurement-based care and flexible dosing with the aim of achieving symptom remission." | 2.74 | Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial. ( Balasubramani, GK; Fava, M; Friedman, ES; Gilmer, W; Nierenberg, AA; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2009) |
| " Phase 1 was a 6-week lead-in with open-label sertraline flexibly dosed to 100 mg (or escitalopram equivalent) to prospectively define treatment refractoriness (lack of remission)." | 2.74 | Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. ( Hoge, EA; Lebeau, RT; Moshier, SJ; Otto, MW; Pollack, MH; Simon, NM; Thompson, EH; Worthington, JJ; Zalta, AK, 2009) |
| "Bupropion SR in the treatment of PTSD had no significant effect in the current sample." | 2.73 | A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. ( Becker, ME; Beckham, JC; Bukenya, DS; Dennis, MF; Hertzberg, MA; Moore, SD, 2007) |
| "Posttraumatic stress disorder (PTSD) is a serious mental illness which exhibits significant impairment of psychosocial and occupational function." | 2.72 | Treatment of chronic posttraumatic stress disorder in combat veterans with citalopram: an open trial. ( Ambrose, S; Davis, LL; English, BA; Jewell, G; Jewell, M, 2006) |
| "Escitalopram was initiated at 10 mg daily for 4 weeks, then increased to 20 mg daily for the remainder of the study." | 2.72 | Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. ( Durkalski, VL; Hamner, MB; Lorberbaum, JP; Robert, S; Ulmer, HG, 2006) |
| " However, subtle differences in improvements in PTSD symptom clusters, physiologic reactivity, and reported adverse events were identified." | 2.71 | Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. ( Burgin, C; Jones, DE; Masters, BK; Parker, DE; Potter-Kimball, R; Tucker, P; Wyatt, DB, 2003) |
| "Treatment with citalopram resulted in significant deactivation in the left medial temporal cortex irrespective of clinical response." | 2.71 | Single photon emission computed tomography in posttraumatic stress disorder before and after treatment with a selective serotonin reuptake inhibitor. ( Hugo, C; Seedat, S; Stein, DJ; van Heerden, B; Van Kradenburg, J; Warwick, J; Zungu-Dirwayi, N, 2004) |
| "At baseline, PTSD subjects had significantly greater PTSD, depression, and IL-1beta and lower IL-2R levels than control subjects, with no group differences found for am or pm cortisol levels." | 2.71 | Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder. ( Hossain, A; Masters, B; Parker, DE; Ruwe, WD; Trautman, RP; Tucker, P; Wyatt, DB, 2004) |
| "The Clinician-Adminstered PTSD Scale (CAPS) and the Clinical Global Improvement Scale (CGI) were used as outcome measures." | 2.70 | Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder. ( Emsley, RA; Kaminer, D; Middleton, T; Rossouw, W; Seedat, S; Stein, DJ; Ziervogel, C, 2002) |
| "Post-traumatic stress disorder (PTSD) is a debilitating disorder which, after a sufficient delay, may be diagnosed amongst individuals who respond with intense fear, helplessness or horror to traumatic events." | 2.50 | Pharmacological interventions for preventing post-traumatic stress disorder (PTSD). ( Amos, T; Ipser, JC; Stein, DJ, 2014) |
| "We also review the history of PTSD and the development of its diagnostic criteria." | 2.44 | Post-traumatic stress disorder and its treatment in children and adolescents. ( Najjar, F; Weisbrot, J; Weller, EB; Weller, RA, 2008) |
| "Brexpiprazole improved complex post traumatic stress disorder in FV victims and needs further evaluation." | 1.56 | Adjunctive therapy with brexpiprazole improves treatment resistant complex post traumatic stress disorder in domestic family violence victims. ( O'Connor, M, 2020) |
| "Posttraumatic stress disorder (PTSD) is a trauma-induced mental disorder characterised by fear extinction dysfunction in which fear circuit monoamines are possibly associated." | 1.43 | Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory. ( Lin, CC; Liu, YP; Tung, CS, 2016) |
| "A total of 15 PTSD patients (36." | 1.35 | [Sleep spindles in post traumatic stress disorder: significant importance of selective serotonin reuptake inhibitors]. ( Dotan, Y; Pillar, G; Suraiya, S, 2008) |
| "However, as his PTSD symptoms remitted, so did his tic symptoms." | 1.35 | Attenuation of apparent new-onset ocular tics with successful treatment of PTSD. ( Drouillard, GJ; Gallagher, MB; Hayes, PC; Weber, CL, 2009) |
| "Measures related to PTSD and depression were obtained before, during, and after treatment." | 1.35 | Diagnosis and treatment of PTSD-related compulsive checking behaviors in veterans of the Iraq war: the influence of military context on the expression of PTSD symptoms. ( Foa, EB; Grubaugh, AL; Hamner, MB; Tuerk, PW, 2009) |
| "Post-traumatic stress disorder (PTSD) is an anxiety disorder that may develop after the experiencing or witnessing of a life-threatening event." | 1.35 | WFS1 gene as a putative biomarker for development of post-traumatic syndrome in an animal model. ( Gispan, I; Kesner, Y; Merenlender, A; Shalit, F; Yadid, G; Zohar, J, 2009) |
| "Citalopram treatment resulted in significant deactivation (p = 0." | 1.32 | Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. ( Carey, PD; Harvey, BH; Niehaus, DJ; Seedat, S; Stein, DJ; van der Linden, G; van Heerden, BB; Warwick, J, 2004) |
| "Citalopram was well-tolerated overall with reported adverse experiences being relatively benign." | 1.31 | An open trial of citalopram in adolescents with post-traumatic stress disorder. ( Kaminer, D; Lockhat, R; Seedat, S; Stein, DJ; Zungu-Dirwayi, N, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (52.38) | 29.6817 |
| 2010's | 17 (40.48) | 24.3611 |
| 2020's | 3 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| O'Connor, M | 1 |
| Na, PJ | 1 |
| Adhikari, S | 1 |
| Szuhany, KL | 1 |
| Chen, AZ | 1 |
| Suzuki, RR | 1 |
| Malgaroli, M | 1 |
| Robinaugh, DJ | 1 |
| Bui, E | 1 |
| Mauro, C | 1 |
| Skritskaya, NA | 1 |
| Lebowitz, BD | 1 |
| Zisook, S | 2 |
| Reynolds, CF | 1 |
| Shear, MK | 1 |
| Simon, NM | 2 |
| Herr, J | 1 |
| Hatch, L | 1 |
| Sephien, A | 1 |
| Hanna, K | 1 |
| Mann, RA | 1 |
| George, AK | 1 |
| Paraschakis, A | 1 |
| Katsanos, AH | 1 |
| Hoşoğlu, E | 1 |
| Akça, ÖF | 1 |
| Jasbi, M | 1 |
| Sadeghi Bahmani, D | 1 |
| Karami, G | 1 |
| Omidbeygi, M | 1 |
| Peyravi, M | 1 |
| Panahi, A | 1 |
| Mirzaee, J | 1 |
| Holsboer-Trachsler, E | 1 |
| Brand, S | 1 |
| Waltereit, R | 1 |
| Eifler, S | 1 |
| Schirmbeck, F | 1 |
| Zink, M | 1 |
| Manteghi, AA | 1 |
| Hebrani, P | 1 |
| Mortezania, M | 1 |
| Haghighi, MB | 1 |
| Javanbakht, A | 1 |
| Jakubovski, E | 1 |
| Bloch, MH | 1 |
| Mauritz, MW | 1 |
| van de Sande, R | 1 |
| Goossens, PJ | 1 |
| van Achterberg, T | 1 |
| Draijer, N | 1 |
| Amos, T | 1 |
| Stein, DJ | 7 |
| Ipser, JC | 1 |
| Suliman, S | 1 |
| Seedat, S | 5 |
| Pingo, J | 1 |
| Sutherland, T | 1 |
| Zohar, J | 2 |
| Ulbricht, CM | 1 |
| Rothschild, AJ | 1 |
| Lapane, KL | 1 |
| Lin, CC | 1 |
| Tung, CS | 1 |
| Liu, YP | 1 |
| Shalev, AY | 2 |
| Ankri, Y | 2 |
| Gilad, M | 1 |
| Israeli-Shalev, Y | 2 |
| Adessky, R | 2 |
| Qian, M | 1 |
| Freedman, S | 2 |
| Schuch, LG | 1 |
| Yip, A | 1 |
| Nouri, KF | 1 |
| Gregersen, M | 1 |
| Cason, B | 1 |
| Kukreja, J | 1 |
| Wozniak, C | 1 |
| Brzezinski, M | 1 |
| Qi, W | 1 |
| Gevonden, M | 1 |
| Shalev, A | 1 |
| Hensley, PL | 1 |
| Slonimski, CK | 1 |
| Uhlenhuth, EH | 1 |
| Clayton, PJ | 1 |
| Dotan, Y | 1 |
| Suraiya, S | 1 |
| Pillar, G | 1 |
| Friedman, ES | 1 |
| Wisniewski, SR | 1 |
| Gilmer, W | 1 |
| Nierenberg, AA | 1 |
| Rush, AJ | 1 |
| Fava, M | 1 |
| Balasubramani, GK | 1 |
| Trivedi, MH | 1 |
| Hayes, PC | 1 |
| Weber, CL | 1 |
| Gallagher, MB | 1 |
| Drouillard, GJ | 1 |
| Tuerk, PW | 1 |
| Grubaugh, AL | 1 |
| Hamner, MB | 2 |
| Foa, EB | 1 |
| Otto, MW | 1 |
| Worthington, JJ | 1 |
| Hoge, EA | 1 |
| Thompson, EH | 1 |
| Lebeau, RT | 1 |
| Moshier, SJ | 1 |
| Zalta, AK | 1 |
| Pollack, MH | 1 |
| Berger, W | 1 |
| Mehra, A | 1 |
| Lenoci, M | 1 |
| Metzler, TJ | 1 |
| Otte, C | 1 |
| Tarasovsky, G | 1 |
| Mellon, SH | 1 |
| Wolkowitz, OM | 1 |
| Marmar, CR | 1 |
| Neylan, TC | 1 |
| Peleg, T | 1 |
| Tucker, P | 2 |
| Potter-Kimball, R | 1 |
| Wyatt, DB | 2 |
| Parker, DE | 2 |
| Burgin, C | 1 |
| Jones, DE | 1 |
| Masters, BK | 1 |
| Warwick, J | 2 |
| van Heerden, B | 1 |
| Hugo, C | 1 |
| Zungu-Dirwayi, N | 2 |
| Van Kradenburg, J | 1 |
| Ruwe, WD | 1 |
| Masters, B | 1 |
| Hossain, A | 1 |
| Trautman, RP | 1 |
| Carey, PD | 1 |
| Niehaus, DJ | 1 |
| van der Linden, G | 1 |
| van Heerden, BB | 1 |
| Harvey, BH | 2 |
| Mullins, CD | 1 |
| Shaya, FT | 1 |
| Meng, F | 1 |
| Wang, J | 1 |
| Harrison, D | 1 |
| Solomons, K | 1 |
| Gooch, S | 1 |
| Wong, A | 1 |
| Uys, JD | 1 |
| Muller, CJ | 1 |
| Marais, L | 1 |
| Daniels, WM | 1 |
| English, BA | 1 |
| Jewell, M | 1 |
| Jewell, G | 1 |
| Ambrose, S | 1 |
| Davis, LL | 1 |
| Robert, S | 1 |
| Ulmer, HG | 1 |
| Lorberbaum, JP | 1 |
| Durkalski, VL | 1 |
| Becker, ME | 1 |
| Hertzberg, MA | 1 |
| Moore, SD | 1 |
| Dennis, MF | 1 |
| Bukenya, DS | 1 |
| Beckham, JC | 1 |
| Markowitz, JD | 1 |
| Kesner, Y | 1 |
| Merenlender, A | 1 |
| Gispan, I | 1 |
| Shalit, F | 1 |
| Yadid, G | 1 |
| Najjar, F | 1 |
| Weller, RA | 1 |
| Weisbrot, J | 1 |
| Weller, EB | 1 |
| Lockhat, R | 1 |
| Kaminer, D | 2 |
| Khouzam, HR | 1 |
| el-Gabalawi, F | 1 |
| Donnelly, NJ | 1 |
| Ziervogel, C | 1 |
| Middleton, T | 1 |
| Emsley, RA | 1 |
| Rossouw, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimizing Treatment for Complicated Grief (Healing Emotions After Loss:HEAL)[NCT01179568] | Phase 2 | 395 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| [NCT00300313] | 450 participants (Anticipated) | Interventional | 2005-06-30 | Completed | |||
| Prevention of Post Traumatic Stress Disorder by Early Treatment[NCT00146900] | 298 participants (Actual) | Interventional | 2004-08-31 | Completed | |||
| Treatment Refractory Panic Disorder[NCT00118417] | Phase 2/Phase 3 | 46 participants (Actual) | Interventional | 1999-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The 19-item self-report instrument assesses symptoms of complicated grief. Responses on individual items are added up to a total score, which can range from 0 to 76 with higher scores indicating more intense symptoms. This scale has been utilized previously in treatment studies of CG. Additional times points include weeks 4, 8, 12, 16, 20 and 40. For the pre-specified analyses we compared change in the ICG total score from baseline (calculated as baseline score minus week 12 score) for CIT vs PLA at week 12 (aim 1), based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 12
| Intervention | score change from baseline to wk12 (Mean) |
|---|---|
| Citalopram (CIT) | 18 |
| Placebo (PLA; Sugar Pill) | 16 |
The 19-item self-report instrument assesses symptoms of complicated grief. Responses on individual items are added up to a total score, which can range from 0 to 76 with higher scores indicating more intense symptoms. This scale has been utilized previously in treatment studies of CG. Additional times points include weeks 4, 8, 12, 16, 20 and 40. For the pre-specified analyses we compared change in the ICG total score from baseline (calculated as baseline score minus week 20 score) for CIT with CGT vs PLA with CGT (aim 2), and for CIT with CGT vs CIT (aim 3) based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 20
| Intervention | score change from baseline to wk20 (Mean) |
|---|---|
| Citalopram (CIT) | 20 |
| Complicated Grief Treatment With Citalopram (CGT With CIT) | 25 |
| Complicated Grief Treatment With Placebo (CGT With PLA) | 26 |
The WSAS is a modification of a scale introduced by Hafner and Marks (1976), consisting of 0-8 point ratings of the extent to which symptoms interfere with five areas of daily functioning: work, home management, private leisure, social leisure, and family relationships. It is a well-validated, widely used self-report measure. Additional time points include weeks 4, 8, 12, 16, and 40. A total score calculated as a sum of all items (possible range 0-40) was used in the analyses with higher scores indicating more impairment. For the pre-specified analyses we compared change in the WSAS total score from baseline (calculated as baseline score minus week 12 score) for CIT vs PLA at week 12 (aim 1), based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 12
| Intervention | score change from baseline to wk12 (Mean) |
|---|---|
| Citalopram (CIT) | 10 |
| Placebo (PLA; Sugar Pill) | 8 |
The WSAS is a modification of a scale introduced by Hafner and Marks (1976), consisting of 0-8 point ratings of the extent to which symptoms interfere with five areas of daily functioning: work, home management, private leisure, social leisure, and family relationships. It is a well-validated, widely used self-report measure. Additional time points include weeks 4, 8, 12, 16, and 40. A total score calculated as a sum of all items (possible range 0-40) was used in the analyses with higher scores indicating more impairment. For the pre-specified analyses we compared change in the WSAS total score from baseline (calculated as baseline score minus week 20 score) for CIT with CGT vs PLA with CGT (aim 2), and for CIT with CGT vs CIT (aim 3) based on the intention-to-treat principle including all randomized participants. (NCT01179568)
Timeframe: Baseline and week 20
| Intervention | score change from baseline to wk20 (Mean) |
|---|---|
| Citalopram (CIT) | 10 |
| Complicated Grief Treatment With Citalopram (CGT With CIT) | 14 |
| Complicated Grief Treatment With Placebo (CGT With PLA) | 16 |
Brief rating scale frequently used in clinical trials. For this study, version modified for complicated grief was be used. Response is defined as a score of 1(very much improved) or 2 (much improved) on the scale. The rating was done by an Independent Evaluator. (NCT01179568)
Timeframe: Weeks 12 and 20
| Intervention | percentage of responders (Number) |
|---|---|
| Citalopram (CIT) | 46 |
| Placebo (PLA; Sugar Pill) | 38 |
| Complicated Grief Treatment With Citalopram (CGT With CIT) | 84 |
| Complicated Grief Treatment With Placebo (CGT With PLA) | 83 |
This measure is the change in points between baseline and endpoint scores on the Panic Disorder Severity Scale (PDSS). The PDSS is a 7-item scale with each item rated from 0 (none) to 4 (extreme), for a total score range of 0 to 28 points, and an established interrater reliability of 0.87. (NCT00118417)
Timeframe: Measured at baseline and after Phase 1 (6 weeks)
| Intervention | Points on a scale (Mean) |
|---|---|
| Moderate Sertraline Treatment | 4.3 |
This measure is the change in points between baseline and endpoint scores on the Panic Disorder Severity Scale (PDSS). The PDSS is a 7-item scale with each item rated from 0 (none) to 4 (extreme), for a total score range of 0 to 28 points, and an established interrater reliability of 0.87. (NCT00118417)
Timeframe: Measured after Phase 1 (Week 6) and Phase 2 (Week 12)
| Intervention | Points on a scale (Mean) |
|---|---|
| Increased Sertraline | 2.36 |
| Sertraline Plus Placebo | 2.31 |
This measure is the change in points between baseline and endpoint scores on the Panic Disorder Severity Scale (PDSS). The PDSS is a 7-item scale with each item rated from 0 (none) to 4 (extreme), for a total score range of 0 to 28 points, and an established interrater reliability of 0.87. (NCT00118417)
Timeframe: Measured after Phase 2 (Week 12) and Phase 3 (Week 24)
| Intervention | Points on a scale (Mean) |
|---|---|
| Medication Optimization | 3.78 |
| Augmented Cognitive Behavior Therapy | 2.9 |
3 reviews available for citalopram and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Antidepressants for Depression Associated with Traumatic Brain Injury: A Meta-analytical Study of Randomised Controlled Trials.
Topics: Antidepressive Agents; Brain Injuries, Traumatic; Citalopram; Depression; Humans; Randomized Control | 2017 |
Pharmacological interventions for preventing post-traumatic stress disorder (PTSD).
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Amines; Anti-Anxiety Agents; Anti-Inflammatory | 2014 |
Post-traumatic stress disorder and its treatment in children and adolescents.
Topics: Adolescent; Child; Child Abuse; Child, Preschool; Citalopram; Clinical Trials as Topic; Clonidine; C | 2008 |
20 trials available for citalopram and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Posttraumatic Distress Symptoms and Their Response to Treatment in Adults With Prolonged Grief Disorder.
Topics: Adult; Aged; Behavioral Symptoms; Citalopram; Combined Modality Therapy; Female; Grief; Humans; Long | 2021 |
Influence of adjuvant mindfulness-based cognitive therapy (MBCT) on symptoms of post-traumatic stress disorder (PTSD) in veterans - results from a randomized control study.
Topics: Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Humans; Iran; Male; Middle Aged | 2018 |
Baclofen add-on to citalopram in treatment of posttraumatic stress disorder.
Topics: Adult; Aged; Baclofen; Citalopram; Double-Blind Method; Drug Therapy, Combination; GABA-B Receptor A | 2014 |
Prognostic subgroups for citalopram response in the STAR*D trial.
Topics: Adult; Aged; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Educational Status; Female; | 2014 |
Escitalopram in the prevention of posttraumatic stress disorder: a pilot randomized controlled trial.
Topics: Adult; Analysis of Variance; Anxiety; Citalopram; Depression; Double-Blind Method; Drug Monitoring; | 2015 |
The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome.
Topics: Adult; Anxiety Disorders; Bulimia; Citalopram; Depression; Feeding and Eating Disorders; Female; Hum | 2015 |
Long-term outcome of early interventions to prevent posttraumatic stress disorder.
Topics: Adolescent; Adult; Aged; Citalopram; Cognitive Behavioral Therapy; Cross-Sectional Studies; Double-B | 2016 |
Efficacy and Tolerability of High-Dose Escitalopram in Posttraumatic Stress Disorder.
Topics: Adult; Citalopram; Female; Humans; Male; Medication Adherence; Middle Aged; Outcome Assessment, Heal | 2017 |
Escitalopram: an open-label study of bereavement-related depression and grief.
Topics: Adult; Aged; Bereavement; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual | 2009 |
Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial.
Topics: Adolescent; Adult; Aged; Black or African American; Citalopram; Demography; Depressive Disorder, Maj | 2009 |
Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial.
Topics: Adult; Anticonvulsants; Citalopram; Clonazepam; Cognitive Behavioral Therapy; Combined Modality Ther | 2009 |
Serum brain-derived neurotrophic factor predicts responses to escitalopram in chronic posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Chronic Disease; | 2010 |
Prevention of posttraumatic stress disorder by early treatment: results from the Jerusalem Trauma Outreach And Prevention study.
Topics: Adult; Citalopram; Cognitive Behavioral Therapy; Double-Blind Method; Early Diagnosis; Female; Human | 2012 |
Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo.
Topics: Adolescent; Adult; Citalopram; Double-Blind Method; Female; Humans; Male; Middle Aged; Selective Ser | 2003 |
Single photon emission computed tomography in posttraumatic stress disorder before and after treatment with a selective serotonin reuptake inhibitor.
Topics: Adult; Brain; Citalopram; Female; Gyrus Cinguli; Humans; Male; Prefrontal Cortex; Psychiatric Status | 2004 |
Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder.
Topics: Adult; Chronic Disease; Circadian Rhythm; Citalopram; Double-Blind Method; Female; Humans; Hydrocort | 2004 |
Treatment of chronic posttraumatic stress disorder in combat veterans with citalopram: an open trial.
Topics: Aged; Citalopram; Combat Disorders; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Sel | 2006 |
Open-label trial of escitalopram in the treatment of posttraumatic stress disorder.
Topics: Citalopram; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Prospective Studies; Ps | 2006 |
A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Attention; Bupropion; Chronic | 2007 |
Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder.
Topics: Adolescent; Adult; Age Factors; Child; Citalopram; Dose-Response Relationship, Drug; Female; Humans; | 2002 |
19 other studies available for citalopram and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Adjunctive therapy with brexpiprazole improves treatment resistant complex post traumatic stress disorder in domestic family violence victims.
Topics: Adult; Citalopram; Combined Modality Therapy; Desvenlafaxine Succinate; Domestic Violence; Drug Resi | 2020 |
27-year-old woman • postpartum seizures • PTSD • history of depression • Dx?
Topics: Adult; Antidepressive Agents; Bupropion; Citalopram; Depression, Postpartum; Female; Humans; Seizure | 2021 |
Recurrent Priapism in a Military Veteran Receiving Treatment for PTSD.
Topics: Adult; Citalopram; Humans; Male; Methylphenidate; Prazosin; Priapism; Psychotropic Drugs; Stress Dis | 2017 |
Escitalopram in the Treatment of a 3-Year-Old Child with Posttraumatic Feeding Disorder.
Topics: Child, Preschool; Citalopram; Feeding and Eating Disorders of Childhood; Humans; Male; Selective Ser | 2018 |
Visual and auditory hallucinations associated with citalopram treatment.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depressive D | 2013 |
Phase-based treatment of a complex severely mentally ill case involving complex posttraumatic stress disorder and psychosis related to Dandy Walker syndrome.
Topics: Adult Survivors of Child Abuse; Antipsychotic Agents; Citalopram; Comorbidity; Dandy-Walker Syndrome | 2014 |
Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory.
Topics: Animals; Anxiety; Brain; Citalopram; Depression; Disease Models, Animal; Fear; Memory; Rats; Rats, W | 2016 |
Serotonin Syndrome Following an Uncomplicated Orthopedic Surgery in a Patient With Post-Traumatic Stress Disorder.
Topics: Adult; Citalopram; Diskectomy; Drug-Related Side Effects and Adverse Reactions; Humans; Low Back Pai | 2016 |
[Sleep spindles in post traumatic stress disorder: significant importance of selective serotonin reuptake inhibitors].
Topics: Citalopram; Electromyography; Electrooculography; Humans; Paroxetine; Reference Values; Selective Se | 2008 |
Attenuation of apparent new-onset ocular tics with successful treatment of PTSD.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Citalopram; Combined Modality Therapy; Humans; | 2009 |
Diagnosis and treatment of PTSD-related compulsive checking behaviors in veterans of the Iraq war: the influence of military context on the expression of PTSD symptoms.
Topics: Adult; Citalopram; Cognitive Behavioral Therapy; Humans; Iraq War, 2003-2011; Male; Military Personn | 2009 |
Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram.
Topics: Adult; Anxiety Disorders; Brain; Citalopram; Female; Humans; Limbic System; Male; Obsessive-Compulsi | 2004 |
Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents; Anxiety Disorders; Citalopram; Cohort Studies | 2005 |
Toxicity with selective serotonin reuptake inhibitors.
Topics: Adult; Chemical and Drug Induced Liver Injury; Citalopram; Depressive Disorder; Female; Fluvoxamine; | 2005 |
Early life trauma decreases glucocorticoid receptors in rat dentate gyrus upon adult re-stress: reversal by escitalopram.
Topics: Aging; Animals; Citalopram; Dentate Gyrus; Disease Models, Animal; Down-Regulation; Glucocorticoids; | 2006 |
Post-traumatic stress disorder in an elderly combat veteran: a case report.
Topics: Age Factors; Aged, 80 and over; Citalopram; Humans; Male; Psychotherapy; Selective Serotonin Reuptak | 2007 |
WFS1 gene as a putative biomarker for development of post-traumatic syndrome in an animal model.
Topics: Amygdala; Animals; Biomarkers; Citalopram; Disease Models, Animal; Freezing Reaction, Cataleptic; Ge | 2009 |
An open trial of citalopram in adolescents with post-traumatic stress disorder.
Topics: Adolescent; Arousal; Citalopram; Combined Modality Therapy; Female; Humans; Male; Personality Assess | 2001 |
The clinical experience of citalopram in the treatment of post-traumatic stress disorder: a report of two Persian Gulf War veterans.
Topics: Adult; Antidepressive Agents; Citalopram; Humans; Male; Stress Disorders, Post-Traumatic; Veterans | 2001 |